NDC12 Frequently Asked Questions

Get concise answers to common questions about the FDA’s 12-digit National Drug Code format, including the 6-4-2 structure, implementation dates, NDC10 conversion, NDC11, labeling, barcodes, drug listing, and organizational readiness.

What does NDC stand for?

NDC stands for National Drug Code.

It is an FDA standard used to identify listed drugs marketed in the United States. An NDC contains separate labeler, product, and package segments.

What is an NDC number?

An NDC is a three-segment identifier associated with a listed drug.

Its segments identify:

The labeler associated with the drug listing.
A specific product, strength, dosage form, and formulation.
The package size and type.

The NDC should be treated as an identifier rather than as an ordinary number used in mathematical calculations.

What is NDC12?

NDC12 is the FDA’s uniform 12-digit National Drug Code format.

It uses a fixed 6-4-2 structure

Six-digit labeler code.
Four-digit product code.
Two-digit package code.

The final rule takes effect on March 7, 2033. On that date, FDA will begin assigning new NDCs in the 12-digit format and convert previously assigned FDA NDCs to the new structure.

Why is FDA changing the NDC format?

FDA is standardizing the NDC because the available supply of five-digit labeler codes is limited and current FDA-assigned NDCs use multiple segment configurations.

The uniform format expands the available supply of labeler and product codes and is intended to reduce the need to convert FDA-assigned NDCs into another standardized representation for use elsewhere in healthcare.

Is NDC12 a new type of drug code?

NDC12 is a new standardized format for the existing National Drug Code system.

The NDC will continue to contain labeler, product, and package segments. The main change is that every standard FDA-assigned NDC will use the same 12-digit, 6-4-2 structure.

Which FDA-assigned NDCs are affected?

The final rule applies to NDCs assigned by FDA to human drugs, including biological products, and animal drugs.

The rule concerns FDA-assigned NDCs. It does not itself revise other NDC representations governed by separate standards, such as the current 11-digit HIPAA reimbursement format.

What is the NDC12 format?

The standard human-readable NDC12 format is:

XXXXXX-XXXX-XX

6 digits Labeler code identifies the organization associated with the listing

4 digits product code identifies the strength, dosage form, and formulation

2 digits package code identifies the package size and type

View the complete NDC12 6-4-2 format.

How many digits are in an NDC?

The number of digits depends on the representation being discussed.

Current FDA-assigned NDCs contain 10 digits.
The representation currently used in HIPAA reimbursement transactions contains 11 digits.
The future FDA-assigned NDC12 format contains 12 digits.

These formats are related, but they should not be treated as interchangeable.

What formats are used for current 10-digit NDCs?

Current FDA-assigned NDC10 codes generally use one of three segment configurations:

4-4-2
5-3-2
5-4-1

The numbers describe the length of the labeler, product, and package segments.

NDC12 replaces these multiple native configurations with one uniform 6-4-2 structure for FDA-assigned NDCs.

How will existing 10-digit NDCs be converted to NDC12?

FDA will add leading zeros to the appropriate labeler, product, or package segment to create the 6-4-2 structure.

Existing structure	NDC10	Converted NDC12
4-4-2	1234-5678-90	001234-5678-90
5-3-2	12345-678-90	012345-0678-90
5-4-1	12345-6789-0	012345-6789-00

Will a converted NDC12 be considered a completely new NDC?

FDA does not consider the addition of leading zeros for the format conversion, by itself, to constitute the assignment of a completely new NDC. The original 10-digit value and its converted 12-digit representation refer to the same underlying FDA-assigned NDC expressed in different formats.

Organizations may still need crosswalks to preserve traceability between the two representations.

What is NDC11?

NDC11 commonly refers to the standardized 11-digit, 5-4-2 representation currently used in HIPAA reimbursement transactions. It is generally created from an FDA-assigned NDC10 by adding a leading zero to the segment that is shorter than the required 5-4-2 structure.

NDC11 should not be confused with the future FDA-assigned NDC12 format.

Is NDC11 the same as NDC12?

No. NDC11 contains five labeler digits, while NDC12 contains six.

Does NDC12 replace the current 11-digit NDC?

The FDA final rule changes FDA-assigned NDCs. It does not itself amend the separate HIPAA transaction standards that currently use an 11-digit NDC representation.

FDA has stated that it expects the current HIPAA standard to be updated before the March 7, 2033, effective date so it can accommodate the new 12-digit format.

Organizations should continue monitoring the authorities responsible for HIPAA transaction standards rather than assuming the FDA rule independently changes those requirements.

How do you convert a 10-digit NDC to an 11-digit NDC?

One leading zero is added to the appropriate NDC10 segment to create the standardized 5-4-2 representation.

NDC10 structure	NDC10	NDC11
4-4-2	1234-5678-90	01234-5678-90
5-3-2	12345-678-90	12345-0678-90
5-4-1	12345-6789-0	12345-6789-00

This is different from the NDC10-to-NDC12 conversion, which produces a 6-4-2 structure.

Can an unformatted 10-digit NDC be converted reliably?

Not always. An unformatted 10-digit value does not display its original labeler, product, and package boundaries. Without that information, a system may not know where the leading zero or zeros belong.

Reliable conversion requires the original segment configuration or another authoritative source that confirms it.

Why are NDC segment boundaries important during conversion?

Segment boundaries show which digits belong to the labeler, product, and package codes.

Leading zeros must be added to the correct segment based on whether the existing NDC uses a 4-4-2, 5-3-2, or 5-4-1 structure. Adding zeros without preserving those boundaries can create an incorrect representation.

When does NDC12 take effect?

The final rule takes effect on March 7, 2033. On that date:

FDA begins assigning new NDCs in the uniform 12-digit format.
Existing FDA-assigned NDCs are converted to the 12-digit format.
Affected systems should be capable of processing NDC12.
The three-year drug-labeling transition begins.

View the complete NDC12 Timeline.

Is March 7, 2033 a confirmed FDA date?

Yes. March 7, 2033 is the effective date established in FDA’s final rule published on March 5, 2026. Earlier articles or resources that describe the effective date as unknown, proposed, or estimated should be updated or clearly marked as historical.

What is the seven-year preparation period?

The preparation period runs from March 5, 2026 through March 6, 2033.

During this period, FDA continues assigning NDCs in the current 10-digit configurations. Affected organizations should use this time to prepare systems, processes, infrastructure, data exchanges, and labeling for the 12-digit format.

Can organizations continue using 10-digit NDCs after March 7, 2033?

Existing 10-digit NDCs may continue to appear on drug labeling during the three-year labeling transition from March 7, 2033 through March 6, 2036.

However, March 7, 2033 remains the system-readiness date. Affected systems should be able to process the new 12-digit format from that date

Do systems need to support both NDC10 and NDC12?

Yes, during the labeling transition. FDA advises affected parties to ensure their systems can process both the 10-digit and 12-digit FDA-assigned formats from March 7, 2033 through March 6, 2036.

What is the difference between the 2033 and 2036 dates?

March 7, 2033 is the rule’s effective date and the point when FDA begins using the new 12-digit format.

March 6, 2036 is the final day of the three-year drug-labeling transition.

Organizations should not treat 2036 as an additional deadline for beginning their system changes.

What happens after March 6, 2036?

FDA states that drugs labeled with a 10-digit NDC after March 7, 2036 may be subject to regulatory action.

This does not mean that every historical 10-digit value must disappear from databases, archives, reports, or audit records. Organizations may still need to retain historical representations for traceability and reconciliation.

Will drug labels need to be updated for NDC12?

Yes. Companies should update labeling to replace the current 10-digit NDC with the 12-digit format by adding leading zeros to the appropriate segments.

The three-year transition is intended to provide time to complete labeling updates and use remaining stock carrying 10-digit NDCs.

When should companies begin using NDC12 on labels?

The labeling transition begins on March 7, 2033.

FDA states that companies should begin applying the 12-digit format to updated labeling as soon as possible once the transition begins.

The transition continues through March 6, 2036.

Can old label stock still be used during the transition?

FDA does not intend to object to continued use of previously assigned 10-digit NDCs on existing drug labeling during the three-year transition.

This permits companies to complete labeling changes and deplete old labeling stock while moving to the 12-digit format.

Does NDC12 change barcode requirements?

The final rule permits either linear or nonlinear barcodes when the barcode conforms to an FDA-recognized standard developed by a widely recognized international standards organization.

Barcode implementation should still be reviewed against the requirements applicable to the specific drug product and packaging.

Can a two-dimensional data matrix carry an NDC12?

Yes. For products subject to Drug Supply Chain Security Act product-identifier requirements, a two-dimensional data matrix may encode the 12-digit NDC using GS1 Application Identifier 715.

The data matrix may also contain required information such as:

Serial number.
Lot number.
Expiration date.

For applicable products, a single two-dimensional data matrix may satisfy both the NDC barcode-label and DSCSA product-identifier requirements beginning March 7, 2033.

What happens to existing FDA drug-listing files?

FDA plans to update its drug-listing files automatically to reflect the 12-digit format on March 7, 2033.
Registrants will not need to submit new or updated listing files solely because FDA converted the NDC format.

Registrants are expected to update their listing files when the corresponding product labeling is updated to include the 12-digit NDC.

Does having an NDC mean that a drug is FDA-approved?

No. Assignment of an NDC or inclusion in the NDC Directory does not, by itself, mean that FDA has approved the drug, verified all submitted information, or determined that the product is eligible for reimbursement.

The NDC is an identifier used for drug listing and related purposes.

Who should prepare for NDC12?

Organizations that assign, store, exchange, display, print, scan, validate, report, or otherwise process FDA-assigned NDCs should assess their readiness.

This may include:

Manufacturers.
Repackagers and relabelers.
Distributors.
Pharmacies.
Healthcare providers.
Payors.
Software and data vendors.
Government agencies.
Supply-chain and trading partners.

The effect will differ by organization. Not every party has the same regulatory or operational responsibility.

How should an organization begin preparing?

Begin with five foundational actions:

Assign program ownership.
Inventory every system and workflow that uses NDCs.
Identify assumptions about length, segments, hyphens, and leading zeros.
Map vendors, integrations, and trading partners.
Create a phased remediation and testing roadmap.

What systems may need to be reviewed?

Any application that creates, stores, validates, transforms, displays, prints, scans, reports, or exchanges NDCs may require review.

Examples may include:

Enterprise resource planning systems.
Product and master-data platforms.
Pharmacy and dispensing systems.
Electronic health record systems.
Warehouse and distribution platforms.
Labeling and artwork applications.
Claims and reimbursement platforms.
APIs, data feeds, reports, and analytics tools.

This is a practical assessment list, not a statement that FDA individually requires changes to every listed system.

Is increasing a database field to 12 characters enough?

Not necessarily.

A system may accept 12 characters while still containing assumptions about:

Current NDC10 segment structures.
NDC11 reimbursement formatting.
Leading-zero removal.
Hyphen placement.
Validation logic.
Matching and duplicate rules.
Reports and exports.
External interfaces.

Readiness requires reviewing the complete workflow, not only the visible field length.

Should an NDC be stored as a number or as text?

It should be stored in a way that preserves every digit, including leading zeros.

Numeric data types may remove leading zeros. In many systems, a text or string field may therefore be more suitable for storing the identifier.

The appropriate technical design will depend on the system, but leading-zero preservation is essential.

When should vendors be contacted?

Vendors should be engaged early enough to understand:

Whether their products will support NDC12.
Planned release dates.
Required customer configuration.
Dual-format capabilities.
Interface and reporting changes.
Testing support.
Dependencies on other products or standards.

Organizations should not assume that every vendor will deliver changes on the same schedule.

Will organizations need to test with trading partners?

Many NDC workflows cross organizational boundaries, so internal testing alone may not be sufficient.

Testing may need to include vendors, data suppliers, customers, payors, providers, distributors, pharmacies, government interfaces, and other trading partners that send or receive NDC data.

Is there a universal NDC12 compliance checklist?

No single checklist will fit every organization. The required work depends on:

How the organization uses NDCs.
Which systems and products are involved.
Its role in the supply chain.
Applicable labeling or listing responsibilities.
External vendors and trading partners.
Related transaction standards.

A readiness assessment should be tailored to the organization’s actual dependencies.

Are there exceptions to the 12-digit NDC format?

FDA permits certain specified human cells, tissues, and cellular or tissue-based products to continue using an alternative NDC format approved by FDA.

This is a limited exception and should not be interpreted as a general exemption for other products or organizations.

Does the rule apply to animal drugs?

Yes. FDA states that the format change affects FDA-assigned NDCs for human drugs, including biological products, and animal drugs.

Does the FDA rule directly change reimbursement standards?

No. The final rule changes the format of NDCs assigned by FDA. It does not itself amend the separate HIPAA transaction standards currently using an 11-digit NDC representation.

Related reimbursement and transaction standards should be monitored separately.

Are there penalties for not preparing for NDC12?

The final rule does not provide one universal penalty schedule for every system, organization, or implementation activity.

FDA specifically states that drugs labeled with a 10-digit NDC after March 7, 2036 may be subject to regulatory action.

Other consequences will depend on the organization’s role, applicable requirements, and the operational effect of being unable to process the new format. Organizations should seek qualified legal or regulatory advice regarding their specific obligations.

Has FDA provided a general extension beyond March 7, 2033?

The current final rule establishes March 7, 2033 as the effective date and provides a seven-year preparation period.

The three-year period through March 6, 2036 is a labeling transition. It should not be treated as a general extension of the system-readiness date.

Where can I find official NDC12 information?

The primary authoritative sources are:

FDA’s National Drug Code Format page.
The final rule, Revising the National Drug Code Format and Drug Label Barcode Requirements.
FDA’s Final Regulatory Impact Analysis.
FDA’s National Drug Code Directory and file definitions.

NDC12.com summarizes and organizes this information but should not replace official FDA materials or professional advice.

Still Have an NDC12 Question?

NDC12.com is an independent educational resource created to reduce uncertainty around the transition to the 12-digit National Drug Code. Submit a question, recommend a correction, or suggest a topic that should be added to this FAQ.